Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction

May 6, 2022
By Marisa C. Weiss
Adam Leitenberger
  • Frank J. Della Croce
  • Melissa Bollmann Jenkins
  • Donna-Marie Manasseh

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement39th Annual Miami Breast Cancer Conference® - Abstracts
Volume 36
Issue suppl 3
Pages: 24

Background

Informed consent is a fundamental ethical and legal requirement to ensure that patients are aware of the risks and benefits of surgical interventions. An effective informed consent process provides adequate information, prioritizes patient comprehension, and facilitates shared decision-making with the goal of optimal patient outcomes and satisfaction.


Objective

We sought to characterize the informed consent process for patients undergoing breast cancer surgery and investigate the extent to which certain elements of the process are associated with patient satisfaction.


Methods

Breastcancer.org visitors and registered online community members in the United States were invited to complete an online survey between August 5 and October 2, 2021. The survey included multiple-choice and rank-order questions about their informed consent and breast cancer surgery experience. All data were deidentified and analyzed in aggregate.


Results

The survey was completed by 2009 adult women diagnosed with breast cancer (mean age, 58 years; 85% White) who had surgery within the past 5 years (mean time since surgery, 17 months). Overall, 42% reported that they were alone when they signed the informed consent form, which was more common during vs before the pandemic (47% vs 34%; P <.05). Patients who were not alone were more likely to report being very/extremely satisfied with their surgical outcomes (61% vs 39%; P <.05). Patients reported being most comfortable when their surgeon was the health care provider who spoke with them before they signed the consent form (91%), as compared with a nurse (79%) or other health care provider (64%). Patients were also more satisfied with surgical outcomes when they felt their surgeons effectively informed them about their surgical options, adequately answered their questions, provided written educational materials, or referred them to reputable online sources. Of patients who were very/extremely satisfied with their surgical outcomes, 92% felt very/extremely well informed at the end of their surgical consultation process.


Conclusions

Patients with breast cancer reported higher satisfaction with surgical decisions when they had a positive informed consent experience that prioritized patient education, comfort, and engagement with the surgeon. This survey highlights the importance of investing in the informed consent process to facilitate shared decision-making for better patient satisfaction with surgical outcomes.

Author Affiliations:

Marisa C. Weiss,1 Adam Leitenberger,2 Frank J. Della Croce,3 Melissa Bollmann Jenkins,4 Donna-Marie Manasseh5

1Chief medical officer/founder, Breastcancer.org; Director of Breast Radiation Oncology, Lankenau Medical Center, Wynnewood, PA
2Editorial director, Breastcancer.org.

3Founding partner, Center for Restorative Breast Surgery, New Orleans, LA
4Community director, Breastcancer.org
5Chief of breast surgery, Maimonides Breast Cancer Center, Brooklyn, NY

Download Issue PDFDownload PDF
Articles in this issue

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients  in a Breast Cancer Registry
15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy  and Symptoms
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
Related Content
Advertisement

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

ONCOLOGY Staff
August 19th 2025
Article

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.


Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

ONCOLOGY Staff
August 18th 2025
Article

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.


Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

ONCOLOGY Staff
August 17th 2025
Article

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.


Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

ONCOLOGY Staff
August 16th 2025
Article

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.


Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025
Article

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

Related Content
Advertisement

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

ONCOLOGY Staff
August 19th 2025
Article

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.


Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma

ONCOLOGY Staff
August 18th 2025
Article

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.


Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

ONCOLOGY Staff
August 17th 2025
Article

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.


Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

Creating Space for Ide-Cel and Finding Sequencing Options in Multiple Myeloma

ONCOLOGY Staff
August 16th 2025
Article

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.


Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025
Article

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.